Inotuzumab ozogamicin clinical trials

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

This study looks at a new medicine, Inotuzumab Ozogamicin (InO), for children aged 1 to 17 with a type of blood cancer called Acute Lymphoblastic Leukaemia (ALL) that has come back. It compares InO to a standard treatment to see which works better and is safer.